The Director of the United States Patent and Trademark Office issued a precedential ruling on May 14, 2026, denying institution of inter partes review (IPR) in Magnolia Medical Technologies, Inc. v. Kurin, Inc., IPR2026-00097, involving U.S. Patent No. 12,138,052 B1. The decision reinforces the Director's view that Leahy-Smith America Invents Act (AIA) reviews are intended to provide a quick and cost-effective alternative to district court litigation, not an additional forum for repeating or expanding invalidity disputes.
The Director denied Magnolia's petition because the petition was viewed as outside the purpose of AIA review and as an attempt to use the Patent Trial and Appeal Board (PTAB) for a repeat validity challenge after the petitioner had already contested validity in district court and lost. Although Magnolia argued that no forum had adjudicated anticipation or obviousness because its invalidity expert was precluded from offering those opinions at trial, the Director rejected the premise that the absence of a jury verdict on those grounds entitled Magnolia to relitigate the issues at the USPTO. The decision is significant because it frames discretionary denial not only around docket efficiency or parallel proceedings, but also around broader public-interest considerations, including the integrity of the patent system, efficient administration of the Office, and Congress's intent that AIA review narrow rather than expand patent disputes.
The Director Reiterates that AIA Review Is Intended as an Alternative to District Court Litigation
Congress created inter partes review and post-grant review through the America Invents Act to provide a quick and cost-effective alternative to district court patent litigation for resolving disputes over patent validity. The Director emphasized that Congress did not intend AIA review to be used for harassment, repeated litigation, administrative attacks, or tactics that prevent market entry. The decision states that repeated litigation and administrative attacks can divert resources from research and development and reduce innovation, contrary to the constitutional purpose of the patent system.
The Director observed that many AIA proceedings now occur in parallel with district court or International Trade Commission (ITC) litigation involving the same patent and cited studies indicating that more than eighty percent of Board proceedings have such parallel litigation. The decision explains that parallel use of the PTAB can be problematic when the same arguments are asserted in both forums, when system art in litigation overlaps with patents or printed publications asserted in AIA review, or when the PTAB proceeding simply adds more invalidity arguments under Sections 102 and 103. In the Director's view, when that occurs, AIA review can increase rather than reduce the time and resources devoted to litigating patent validity.
The Director's Public-Interest Framing
The decision places substantial weight on the public-interest role of AIA reviews. The Director explained that AIA reviews are not solely private disputes between litigants because the Office institutes review to reconsider its own patent-grant decision and to correct possible error in the original grant. The decision also states that courts remain the primary forum for adjudicating private disputes and that private litigants retain the right to challenge patents in district court even when AIA review is denied.
The Director cited statutory considerations that focus on the economy, efficient administration of the Office, the Office's ability to timely complete AIA reviews, and the integrity of the patent system. The decision further emphasized that the Director has significant discretion over institution decisions and quoted Federal Circuit and Supreme Court authority stating that no law compels institution and that Congress committed institution decisions to the Director's unreviewable discretion. This public-interest framing suggests that discretionary-denial briefing may increasingly need to address why institution serves the patent system and the Office's limited resources, rather than focusing only on the parties' litigation positions.
The Instant Case
In the Magnolia proceeding, the challenged patent had already been litigated in district court, where a jury found the patent not invalid. Kurin argued that Magnolia's anticipation and obviousness grounds were not presented to the jury because the district court had precluded testimony from Magnolia's invalidity expert. The Director noted that Magnolia's district court anticipation and obviousness grounds were similar to those presented in the IPR petition.
Magnolia argued that the preclusion of its expert's anticipation and obviousness opinions favored institution because no forum had adjudicated validity or patentability under Sections 102 or 103. The Director disagreed, stating that the absence of a jury verdict on anticipation or obviousness did not entitle Magnolia to relitigate the same issues at the Office. The Director further reasoned that allowing such relitigation would conflict with Congress's stated goal that AIA review function as a litigation alternative.
The timing and reason for the expert preclusion were central to the Director's analysis. The petition was filed only after the district court precluded Magnolia's expert on November 3, 2025. The Director noted that the expert was precluded because he failed to disclose the claim construction underlying his anticipation and obviousness opinions, which the Director characterized as something within Magnolia's control. On that record, the Director concluded that Magnolia had the opportunity to fully and fairly litigate the issues in district court, did so, lost, and then attempted to use the Office as a repeat challenge or "second bite at the apple" to undo the litigation loss.
How the Instant Case Fits with Recent USPTO Guidance and Decisions
The decision situates the denial within a broader line of Director guidance and precedential or informative decisions concerning discretionary denial. The Director identified several illustrative categories, including substantial examiner error, inconsistent claim construction positions across forums, foreign sovereign petitioners or real parties in interest, and settled expectations. The decision states that a substantial showing of apparent examiner error can overcome other factors that suggest discretionary denial. It also states that unexplained differences between claim construction positions in district court and at the Board can undermine predictability and certainty in the patent system.
The decision also references recent guidance encouraging parties to discuss American manufacturing and small-business considerations in discretionary briefing. The Director explained that this information can help the Office analyze whether AIA reviews provide a tactical advantage to companies that neither manufacture in the United States nor invest in American manufacturing. The decision further notes that petitioners sued for infringement are encouraged to identify themselves as small businesses so the Office can better understand how frequently such businesses use AIA reviews defensively and weigh that information as part of discretionary considerations.
Practical Implications for Patent Litigants
This decision underscores that the Director may deny institution where an IPR petition appears to follow, rather than replace, district court litigation. The ruling signals that petitioners should not assume that unadjudicated invalidity grounds under Sections 102 or 103 will warrant institution if those grounds could have been litigated in court and the petitioner's failure to present them resulted from litigation choices or procedural shortcomings. For both petitioners and patent owners, discretionary-denial strategy should account for the Director's increasingly explicit focus on whether institution advances the public-interest purposes of AIA review, rather than merely providing additional leverage in private litigation.
Patent challengers should evaluate IPR timing and strategy before committing to district court invalidity positions because the Director treated a post-loss petition raising similar invalidity issues as inconsistent with the AIA's role as a litigation alternative. A petitioner that waits until after an adverse litigation development to file at the PTAB may face an argument that it is seeking a repeat challenge rather than an alternative forum. That risk may be especially acute where the adverse litigation development resulted from conduct within the petitioner's control, as the Director emphasized the expert's failure to disclose the claim construction underlying his invalidity opinions.
Patent owners should consider discretionary-denial arguments that focus on the petitioner's prior opportunity to litigate, the overlap between court and PTAB invalidity theories, the resources already expended in district court, and whether the petition functions as a second attempt to obtain a different outcome. Patent owners may also wish to frame discretionary denial around the public interest, including efficiency, predictability, and the integrity of the patent system. Where relevant, patent owners can point to recent Director guidance and decisions addressing parallel proceedings, inconsistent positions, settled expectations, examiner error, foreign sovereigns, United States manufacturing, and small-business considerations.
Lea Speed continues to monitor this evolving area of discretionary denials in AIA proceedings and remains available to provide guidance on how the Director's decisions should figure into PTAB strategy, district court invalidity planning, and discretionary-denial arguments.